#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

<b>FORM</b>	8-	K
-------------	----	---

#### CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 8, 2023

	UPEXI, INC.			
(Exact name of registrant as specified in its charter)				
Nevada	333-25526	83-3378978		
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)		
	17129 US Hwy 19 N. <u>Clearwater, FL 33760</u> (Address of Principal Executive Offices) (Zip Code)			
	(701) 353-5425 (Registrant's telephone number, including area code)			
(Fo	Not Applicable ormer name or former address, if changed since last report)			
☐ Pre-commencement communications pursuant to Rule	he Securities Act (17 CFR 230.425)	c		
Securities registered pursuant to Section 12(b) of the Act:				
Title of each class  Common Stock, par value \$0.001	Trading Symbol(s) UPXI	Name of each exchange on which registered NASDAO		
Indicate by check mark whether the registrant is an emerging the Securities Exchange Act of 1934 (§240.12b-2 of this chap Emerging growth company ⊠		`		
If an emerging growth company, indicate by check mark if t accounting standards provided pursuant to Section 13(a) of the		period for complying with any new or revised financial		

#### Item 7.01 Regulation FD Disclosure

#### Item 8.01 Other Events.

On May 8, 2023, the Company updated its investor presentation and posted the presentation on its investor relations website. A copy of which is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein.

The information in Item 7.01 and Item 8.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be deemed incorporated by reference in any of the Company's filings under the Securities Act, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference to this Report in such filing.

#### Section 9 – Financial Statements and Exhibits

#### Item 9.01 Financial Statements and Exhibits.

Exhibit No.	Exhibit Description
99.1	Investor Presentation, dated May, 2023
104	Cover Page Interactive Data File (embedded within the Inline XBRL Document)
	3

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

UPEXI, INC.

Dated: May 8, 2023

/s/ Andrew J. Norstrud Name: Andrew J. Norstrud Title: Chief Financial Officer



### **Forward Looking Information**

This presentation contains "forward-looking statements", including statements regarding Upexi, Inc. and its subsidiaries, within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. All of the statements in this presentation, including financial projections, whether written or oral, that refer to expected or anticipated future actions and results of Upex are forward-looking statements. In addition, any statements that refer to expectations, projections, or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements reflect our current projections and expectations projections will prove to be correct.

The information provided in this presentation does not identify or include any risk or exposures, of Uperi that would materially adversely affect the performance or risk of the company. By their nature, forward-looking statements and financial projections involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward-looking information will not occur, which may cause the Company's actual performance and financial results in fluture periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements and financial projections. Innovant factors that could cause actual results to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements and financial projections. Innovant factors that could cause actual results to differ materially from expectations include, but are not limited to business, economic and capital market conditions, the heavily regulated industry in which Upexi carries on business; current or future laws or regulations and new interpretations of existing laws or regulations (legal and regulatory requirements, market conditions and the demand and pricing for our products, our relationships with our customers and business partners; our ability to successfully define, design and release new products in a timely manner that meet our customers' needs, our ability to attract, retain and motivate qualified personnel; competition in our industry, failure of counterparties to perform their contractual obligations; systems, networks, telecommunications or service disruptions or failures or cyber-attack; ability to obtain additional financing on reasonable terms or at all; litigation costs and outcomes, our ability to successfully maintain and enforce our intellectual property rights and defend third party claims o

All information contained in this presentation is provided as of the date of the presentation and is subject to change without notice. Neither Upexi, nor any other person undertakes any obligation to update or revise publicly any of the forward-looking statements and financial projections set out herein, whether as a result of new information and not an investment recommendation. This presented as a source of information and not an investment recommendation. This presentation does not take into account not does it by provide any tax, legal or investment advice or opinion regarding the specific investment objectives or financial situation of any person. Upexi reserves the right to amend or replace the information contained herein, in part or entirely, at any time, and undertakes no obligation to provide the recipient with access to the amended information or to notify the recipient thereof.

The Company discloses and uses the above-mentioned non-GAAP financial measures internally as a supplement to GAAP financial information to evaluate its operating performance, for financial planning purposes, to The Company discloses and uses the above-mentioned non-GAAP financial measures internally as a supplement to GAAP financial information to evaluate its operating performance, for financial planning purposes, to used by investors. Non-GAAP adjusted EBITDA is defined as GAAP net income or net loss before interest, taxes, depreciation and amortization (EBITDA) adjusted for the non-cash stock compensation and stock option expense, acquisition, integration 8 restructuring expenses, charges and gains or losses from extinguishment of debt and other non-cash items, Non-GAAP EBITDA and non-GAAP adjusted EBITDA in non-GAAP adjusted EBITDA may not terms defined by GAAP and, as a result, the Company's measure of non-GAAP EBITDA and non-GAAP adjusted EBITDA may non-GAAP in an expense of the company's performance, financial position, or cash flow that either excludes or includes amounts that are not normally included in the most directly companable measure calculated and presented in accordance with GAAP. The non-GAAP financial measures considered in addition to, and not as a substitute for, or superior to net income or net loss as reported for GAAP on the Consolidated Statements of Operations, cash and cash flows on the Consolidated Statement of Cash Flows or other measures of financial performance prepared in accordance with GAAP. The enon-GAAP financial measures are not a substitute for or presented in lieu of financial in measures provided by CAAP and as reflected on the Company's financial internation pursuant to GAAP should be read to obtain a comprehensive and thorough understanding of the Company's financial resources of the reconciliations of non-GAAP EBITDA and non-GAAP adjusted EBITDA in the highlights or elsewhere are provided in the schedules that are a part of this document



### **Forward Looking Information**

Statements in this presentation that are not descriptions of facts are forward-looking statements relating to future events. Statements may contain certain forward-looking statements pertaining to future anticipated or projected plans, performance and developments, as well as other statements relating to future operations and results. Any statements in this presentation that are not statements of historical fact may be considered to be forward-looking statements. Words such as "may," "will," "expect," "believe," "anticipate," "estimate," "intends," "goal," "distept," "attempt," or variations of these or similar words identify forward-looking statements. These forward-looking statements by their nature are estimates of future results only and involve substantial risks and uncertainties, including but not limited to risks associated with the uncertainties of the statement of their femanical results, additional financing requirements, successful implementation and completion of the Company's growth strategy, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties.

The material included with this document does not consider the specific investment objectives, financial situation, or needs of a specific recipient. This document may not be construed as either a recommendation or an offer to buy or sell securities, nor does it constitute are recommendation or an offer to buy or sell securities. Further, such material is insufficient to form the basis or an investment decision, should not be used by the recipient for that purpose, does not constitute nor should it be construed as research, investment advice or an invitation to conduct any investment business. Read the offering memorandum carefully before investing. It contains Company's objectives, risks, charges, expenses, and other information, which should be considered carefully before investing. You may obtain the offering memorandum contacting your Paulson's representative.





### **About Our Brands**

#### Vita-Medica

- Health and Wellness Brand
- Purchased in late 2021
- 88% Organic Growth since Purchase
- 2022 Organic growth rate of 50%
- Growth Opportunity: acne product launch in 2023





## **Lucky Tail**

- Pet Category Brand
- Amazon and Direct to Consumer platforms
- Significant existing consumer base
- 50% Organic Growth 2022
- Growth Opportunity: Pet Supplement Launch Mid 2023







### **Tytan Tiles**

- Children's STEM Toy Brand
- Purchased in October 2022
- 100% Organic Growth 2022
- 50+% Organic growth anticipated 2023
- Launched in 1,900 Walmart stores in Jan 2023 w/ 3,900 stores planned in H2' 2023
- Growth Opportunity: planned 2023/2024 launch of four new products







### **Proprietary Technology & Data Platform**

- · Platform focuses on building a high-growth portfolio of patents for single click-to-opt-in technology via Interactive Offers business segment
- Purchased in 2022
- · Success to date is rooted in our technology and data
- · Own significant amount of consumer data, allowing us to increase cross-selling between our growth portfolio and brands<sup>1</sup>
- Growth Opportunity: ability to advertise and acquire more customers at reduced cost

The effectiveness of using consumer data to increase cross-selling cannot be guaranteed, and the term "significant" is subjective.





## **Cygnet Online**

- High volume Amazon brand liquidator
- Purchased in Q2' 2022
- High volume Amazon seller in \$600B liquidation
- Focus has been on health, wellness, and over-thecounter (OTC) products
- Expanding into new verticals including electronics, home, and high-margin luxury goods
- Contributed revenues of ~\$22M in 9 months of 2022
- Growth Opportunity: new categories and faster flow-through of purchased products









- Specializes in liquidation of overstocked and discontinued merchandise for hundreds of retailers
- Purchased in October 2022 with \$35M in trailing 12-month revenue
- Buys products at deep discount and liquidates into partner sellers
- **Growth Opportunity:** category expansion for increased flow-through and sales

### Partnerships include:




— and many more!





### **Brand Buyer\***





\$261 billion Global market in 20221

**Pet Care Products** 

- 60-80% Gross Margin<sup>4</sup>
- Projected 6.1% CAGR<sup>1</sup>



#### Wellness + Nutrition

- \$113.80 billion Global market in 2022
- 70-80% Gross Margin<sup>4</sup>
- Projected 9.3% CAGR<sup>2</sup>



#### **Educational Toys**

- \$50 billion Global market in 2023
- 40-60% Gross Margin<sup>4</sup>
- 7.4% CAGR3

https://commonthreadco.com/blogs/coachs-corner/pet-industry-trends-growth-ecommerce-marketing
https://www.research.andmarkets.com/seports/53562/health-and-wellness-food-market-nesearch-report-by
https://www.thebusinessresearch.company.com/report/learning-and-education-top-s-global-market-report
Ranges based off management's internal estimates
"While the numbers presented are global figures, it should be noted that the company mainly operates in the United States. They are expanding into the UK,
the intent of further worktwide expansion. Regional financial performance may vary due to factors beyond the company's control.

Canada, and Australia with





### **Acquisition Targets: What We Look For**

- High margin businesses with success in product categories to match existing portfolio
- Data rich customer lists and ability to leverage databases for cross selling between brands
- Quality management and team to stay on and help us grow for the future
- Synergies for R&D, product development and cross marketing
- Non-Discretionary business verticals to enhance or expand our sales channels



### **Acquisition Targets: What we offer**<sup>1</sup>

- We offer a plug and play model for growth
- We staff a full tech development team for technology integration
- We staff full teams for advertising, marketing, and product development
- Liquidity event for sellers, a second liquidity opportunity in Upexi stock in the future

Most small to midsize brands struggle to afford full teams and we leverage our teams across brands for cost efficiencies and stronger growth opportunities<sup>2</sup>

Future adverse events could affect the company's operations, negatively impacting their ability to offer the entire list of services to target companies. Leveraging teams across brands for cost efficiencies may not guarantee stronger growth opportunities for all brands.





### **Brand Liquidator**

Excess Inventory is a problem for big business.1

Upexi has created a solution to buy excess inventory to sell into our networks, creating distribution for our partners and profits for us.1

- Amazon and wholesale liquidation brand and business
- We do large scale liquidations for retail and brands
- Large revenue opportunities with good margins<sup>2</sup>
  - \$644 Billion Market for Amazon Resellers<sup>3</sup>
  - Market has more than doubled since 2008<sup>3</sup>
- Excess inventory ties up resources, increases costs, and limits a business's ability to respond to changes in demand, potentially leading to financial losses.

  The actual revenue obtained from any opportunity may vary based on a variety of factors. The phrase "good margins" is subjective and there is no guarantee of any specific level of red resources.

  https://www.cnbc.com/2022/02/l9/liquidation-services-resell-returned-items-a-644-billion-business.html





### Why This Matters...

The new digital economy has created a boom of products and small Brands, but competition is increasing and large scale is needed to compete in the future.<sup>1</sup>

We have created a platform that can consolidate successful Brands that are poised for accelerated growth.2

Economies of scale give us a significant opportunity for future growth and cost efficiencies.<sup>3</sup>

- We buy at 3-5 times EBITDA, Consolidate Public Multiples significantly higher<sup>4</sup>
- Increased corporate contribution margin and EBITDA with each acquisition<sup>5</sup>
- Overall Enterprise value should increase with future organic growth and future acquisitions<sup>3</sup>

- Large scale may provide a competitive advantage, but the ability to compete in the future is subject to uncertainties and risks beyond the company's control.

  Consolidation of brands and their success cannot be guaranteed. The term "successful" is subjective and does not guarantee objective measures of success.

  Adverse events could negatively impact the company's growth performance. Actual results are subject to uncertainties and risk beyond the company's control.

  Acquisition multiples are based on management assumptions and will vary for each individual acquisition. The assumption that consolidation will increase multiples is based on the idea that it can lead to a reduction in competition and an increase in market power for the merged companies.

  The Company projects each acquisition to provide increased contribution margin from increased revenues and cost synergies, which will add to their total EBITDA figure. There is significant risk that costs
- associated with acquisitions, such as integration costs, can offset some of the benefits.



### **Experienced Management Team<sup>1</sup>**

**Thomas Williams** 

Lawrence H Dugan

Chairman of Audit Committee

25+ years of accounting experience

35+ years of experience, specialized in securitization mechanisms of illiquid assets

Insider Ownership: 54%<sup>2</sup>

#### **Allan Marshall**

#### Chief Executive Officer

30+ years of M&A focused experience Founder of XPO Logistics, Transportation Services, Inc., and Segmentz, Inc.

#### **Andrew Norstrud**

#### hief Financial Officer

Experienced executive, focused on integrating strategic acquisitions and structure implementation for public companies

#### Gene Salkind, M.D.


#### Board of Directors

Chairman of Compensation Committee Practicing Neurosurgeon, Intuitive Surgical Pharmacyclics

Management team's experience may not directly correlate to this company's business model and does not ensure success On a fully diluted basis, pending shares exercisable within 60 days of November 30, 2022.










# Financial Highlights<sup>1</sup>

Stock Price:	\$4.12 (as of 3/27/23)
Common Stock:	17,960,748 (as of 12/31/22)
Market Cap:	\$74 million
Fiscal 2022 Revenue (ended June 30, 2022):	\$44.6 million
Fiscal Q2 '23 (ended December 31, 2022):	\$27.1 million
Calendar 2023 Revenue Guidance:	\$100 million
Fiscal Q1 2023 GP Margins:	52%
Revenue Growth Rate through '24:	50% -100%



**92% CAGR** 

Financial forecast is based on management estimates only. Adverse events could negatively impact the Company's future financial performance.
Includes discontinued operations revenue
https://www.prnewswire.com/news-releases/upexi-reports-record-revenue-of-Z7-1-million-for-fiscal-2023-second-quarter-an-increase-of-444-year-over-year-301746845.html





# **Thank You**

Contact Us: upexi@kcsa.com





